Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 2608 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi^1,2, Shinsuke Yasuda¹, Ryo Hisada¹, Kazumasa Ohmura¹, Sanae Shimamura¹, Yuka Shimizu¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Miho Suzuki³, Yoshihiro Matsumoto⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Product research department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ⁴Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Consecutive RA patients who initiated treatment with TCZ between December 2013 and September 2015 were enrolled in our prospective study. All patients met 2010…
Abstract Number: 2611 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers¹, Sara Gale², Micki Klearman², Khaled Sarsour² and Sebastian Schneeweiss¹, ¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for cardiovascular (CV) disease. Patients using tocilizumab (TCZ) may experience increased serum lipid levels. It…
Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting
Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database
Tatsuya Atsumi¹, Yoshiaki Ando², Yukiko Hayashi², Shinichi Matsuda², Riwa Tanaka², Nobuhiro Takagi² and Ayako Nakasone², ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
Abstract Number: 496 • 2015 ACR/ARHP Annual Meeting
Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Increased serum lipid levels in patients being treated with tocilizumab (TCZ) is known from several clinical trials1,2. It is not known whether additional methotrexate…
Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
Abstract Number: 569 • 2015 ACR/ARHP Annual Meeting
Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy
Byeongzu Ghang¹, Doo-Ho Lim², Soo Min Ahn³, Wook Jang Seo⁴, Seokchan Hong³, Yong-Gil Kim², Chang-Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is an effective drug for the treatment of rheumatoid arthritis (RA). During administration of tocilizumab, previous studies have…
Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting
Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis
Masao Sato¹ and Masao Takemura², ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Matsunami Reserch Park, Gifu, Japan
Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
Abstract Number: 588 • 2015 ACR/ARHP Annual Meeting
Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Jun Kikuchi, Akiko Shibata, Ryota Sakai, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Tocilizumab (TCZ) is clinically effective against rheumatoid arthritis (RA) and over 50% of RA patients who had completed 5 years of TCZ treatment maintained…
Abstract Number: 593 • 2015 ACR/ARHP Annual Meeting
Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Xavier Teitsma¹, Johannes Jacobs², Paco Welsing³, Thasia Woodworth⁴, Attila Pethö-Schramm⁵, Michelle Borm⁶, Corrado Bernasconi⁵, Floris Lafeber¹ and Johannes W J Bijlsma⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department Rheumatology and clinical immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Joint damage and functional disability can be reduced by intensive treatment of newly diagnosed rheumatoid arthritis (RA) patients during the "window of opportunity". Although…
Abstract Number: 600 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Disease Activity in Rheumatoid Arthritis
Virginia Ruiz-Esquide¹, Pascal Zufferey², Jose Inciarte-Mundo¹, Jordi Yagüe³, M. Victoria Hernández⁴, Julio Ramirez¹, Jeanne Berner², Mariona Pascal³, Andrea Cuervo¹, Juan D. Cañete⁵ and Raimon Sanmarti^1,6, ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Immunology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Hospital Clínic i Provincial, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6R monoclonal antibody approved for the treatment of active rheumatoid arthritis (RA) (EMA: 8mg/kg q4w). Response to treatment may…
Abstract Number: 613 • 2015 ACR/ARHP Annual Meeting
Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis
Hiroaki Niiro¹, Hiroshi Tsukamoto², Yojiro Arinobu², Mitsuteru Akahoshi², Hiroki Mitoma², Kensuke Oryoji³, Yasushi Inoue⁴, Takuya Sawabe⁵, Shuji Nagano⁶, Hiroaki Nishizaka⁷, Seiji Yoshizawa⁸, Yoshifumi Tada⁹, Shigeru Yoshizawa¹⁰, Takeshi Otsuka¹¹, Akira Ueda¹², Hitoshi Nakashima¹³, Takahiko Horiuchi¹⁴ and Koichi Akashi², ¹Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³The Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁴Department of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ⁵Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan, ⁶Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁷Kitakyushu Municipal Medical Center, Kitakyushu, Japan, ⁸Hamanomachi Hospital, Fukuoka, Japan, ⁹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ¹⁰Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, ¹¹Munakata Medical Association Hospital, Munakata, Japan, ¹²Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan, ¹³Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ¹⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Despite their profound inhibitory effects on inflammation and bone destruction, it remains unclear whether biological therapies can improve the long-term prognosis of patients with…
Abstract Number: 1602 • 2015 ACR/ARHP Annual Meeting
Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study
Gorica Ristic¹, Vesna Subota², Petar Ristic³, Dejana Stanisavljevic⁴, Arsen Ristic⁵, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Department of Endocrinology, Military Medical Academy, Belgrade, Serbia, ⁴Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia, ⁵Department of Cardiology, Clinical Center of Serbia & Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Insulin resistance (IR) is increased and β-cell function impaired in rheumatoid arthritis (RA). The aim of this study was to evaluate whether treatment with…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting
Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Jose L. Pablos¹, Navarro Sarabia F², Francisco J. Blanco³, Jose Andres Roman Ivorra⁴, Alberto Alonso⁵, Emilio Martin-Mola⁶ and Miguel Cantalejo-Moreira⁷, ¹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ²Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ³Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology, H.U. P. La Fe, Valencia, Spain, ⁵H Cruces, Baracaldo, Spain, ⁶H La Paz, Madrid, Spain, ⁷Rheumatology Unit, Hospital de Fuenlabrada, Fuenlabrada, Spain
Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…
Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Dimitrios A. Pappas^1,2, Ani John³, Carol J. Etzel^2,4, Chitra Karki², YouFu Li⁵, Joel M. Kremer⁶, Tmirah Haselkorn³ and Jeffrey D. Greenberg^2,7, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc, South San Francisco, CA, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].